A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME.
Prenalterol has been studied across 15 research domains including 🫘 Kidney, ❤️ Cardiovascular, 🧠 Focus & Attention, 🫁 Respiratory, 🌤️ Mood & Depression. The primary research focus is 🫘 Kidney with 75% of studies addressing this area.
The following compounds share molecular targets with Prenalterol, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Prenalterol is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.